Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR(−)/HER2(+) breast cancers

HER2-positive (HER2(+)) breast adenocarcinomas are a heterogeneous group in which hormone receptor (HR) status influences therapeutic decisions and patient outcome. By combining genome-wide RNAi screens with regulatory network analysis, we identified STAT3 as a critically activated master regulator...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Barrueco, Ruth, Yu, Jiyang, Saucedo-Cuevas, Laura P., Olivan, Mireia, Llobet-Navas, David, Putcha, Preeti, Castro, Veronica, Murga-Penas, Eva M., Collazo-Lorduy, Ana, Castillo-Martin, Mireia, Alvarez, Mariano, Cordon-Cardo, Carlos, Kalinsky, Kevin, Maurer, Matthew, Califano, Andrea, Silva, Jose M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536311/
https://www.ncbi.nlm.nih.gov/pubmed/26227964
http://dx.doi.org/10.1101/gad.262642.115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536311/
https://www.ncbi.nlm.nih.gov/pubmed/26227964
http://dx.doi.org/10.1101/gad.262642.115

Ejemplares similares